KR101964954B1 - 뉴로트로핀 수용체의 효현제 및 약제로서의 이의 용도 - Google Patents

뉴로트로핀 수용체의 효현제 및 약제로서의 이의 용도 Download PDF

Info

Publication number
KR101964954B1
KR101964954B1 KR1020137008259A KR20137008259A KR101964954B1 KR 101964954 B1 KR101964954 B1 KR 101964954B1 KR 1020137008259 A KR1020137008259 A KR 1020137008259A KR 20137008259 A KR20137008259 A KR 20137008259A KR 101964954 B1 KR101964954 B1 KR 101964954B1
Authority
KR
South Korea
Prior art keywords
disease
compound
compound according
pharmaceutically acceptable
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137008259A
Other languages
English (en)
Korean (ko)
Other versions
KR20130106384A (ko
Inventor
파블로 빌로스라다
앤젤 메젠구어
Original Assignee
바이오뉴레 파르마, 에스.엘.
콘세호 수페리오르 데 인베스티가시오네스 시엔티피카스
인스티튜트 디＇인베스티가시온스 바이오메디퀘스 아우구스트 피 아이 수니에르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오뉴레 파르마, 에스.엘., 콘세호 수페리오르 데 인베스티가시오네스 시엔티피카스, 인스티튜트 디＇인베스티가시온스 바이오메디퀘스 아우구스트 피 아이 수니에르 filed Critical 바이오뉴레 파르마, 에스.엘.
Publication of KR20130106384A publication Critical patent/KR20130106384A/ko
Application granted granted Critical
Publication of KR101964954B1 publication Critical patent/KR101964954B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020137008259A 2010-08-31 2011-08-31 뉴로트로핀 수용체의 효현제 및 약제로서의 이의 용도 Active KR101964954B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37882310P 2010-08-31 2010-08-31
US61/378,823 2010-08-31
PCT/IB2011/002562 WO2012028959A1 (en) 2010-08-31 2011-08-31 Agonists of neurotrophin receptors and their use as medicaments

Publications (2)

Publication Number Publication Date
KR20130106384A KR20130106384A (ko) 2013-09-27
KR101964954B1 true KR101964954B1 (ko) 2019-04-03

Family

ID=45048148

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137008259A Active KR101964954B1 (ko) 2010-08-31 2011-08-31 뉴로트로핀 수용체의 효현제 및 약제로서의 이의 용도

Country Status (19)

Country Link
US (3) US8791076B2 (enExample)
EP (1) EP2611775B8 (enExample)
JP (1) JP5946454B2 (enExample)
KR (1) KR101964954B1 (enExample)
CN (1) CN103270022B (enExample)
AU (1) AU2011298091B2 (enExample)
BR (1) BR112013004662B8 (enExample)
CA (1) CA2809774C (enExample)
DK (1) DK2611775T3 (enExample)
ES (1) ES2575684T3 (enExample)
HR (1) HRP20160553T1 (enExample)
HU (1) HUE029393T2 (enExample)
IL (1) IL224972A (enExample)
MX (1) MX340233B (enExample)
PL (1) PL2611775T3 (enExample)
PT (1) PT2611775E (enExample)
RU (1) RU2606622C2 (enExample)
SI (1) SI2611775T1 (enExample)
WO (1) WO2012028959A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289886A1 (en) * 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoid agonists of nerve growth factor and their use as medicaments
WO2012028959A1 (en) 2010-08-31 2012-03-08 Pablo Villoslada Agonists of neurotrophin receptors and their use as medicaments
US20160193296A1 (en) * 2012-12-19 2016-07-07 Brown University Methods for treatment of microcephaly associated autism disorders
EP2950095B1 (en) * 2014-05-28 2018-08-29 Technische Universität Dresden Cell-based assay and screening methods for modulators of p75NTR signaling
EP3504209A4 (en) * 2016-08-25 2020-04-29 Pharmatrophix Inc. METHODS AND COMPOUNDS FOR THE TREATMENT OF ALCOHOL USE DISORDERS AND RELATED ILLNESSES
KR101821118B1 (ko) 2016-09-06 2018-01-23 가톨릭대학교 산학협력단 감보그 산(gambogic acid)을 포함한 알러지성 질환 예방 또는 치료용 조성물
CN107802823A (zh) * 2017-10-27 2018-03-16 胡军 Sh2b衔接蛋白1在治疗帕金森病中的功能应用
WO2020018700A1 (en) * 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
JP2022510736A (ja) 2018-12-05 2022-01-27 株式会社スコヒアファーマ 大環状化合物とその使用
TW202116297A (zh) * 2019-07-03 2021-05-01 西班牙商布爾奴爾法碼有限公司 組合療法之方法、組成物與套組
JP2022548337A (ja) * 2019-09-03 2022-11-17 ピーター ジェイ． シークマイヤー， グルタミン酸受容体アゴニストにより認知機能を増加させる方法
TW202131914A (zh) 2019-10-30 2021-09-01 西班牙商布爾奴爾法碼有限公司 用於神經疾病或病狀的治療之新治療方案
IL315955A (en) 2022-03-30 2024-11-01 Peptidream Inc Peptide complex having trkb binding activity
IL321571A (en) * 2022-12-22 2025-08-01 Oculis Operations S?Rl Synthesis of small molecules that are agonists for neurotrophins

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU189214B (en) 1983-01-20 1986-06-30 Alkaloida Vegyeszeti Gyar,Hu Process for preparing pyrroline and pyrrolidine carboxamide derivatives
US6271205B1 (en) 1994-09-21 2001-08-07 University Of Massachusetts Medical Center Cancer treatment by expression of differentiation factor receptor
US5747458A (en) 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands
US6391871B1 (en) 1996-09-20 2002-05-21 John W. Olney Preventing neuronal degeneration in Alzheimer's disease
DE19751062A1 (de) 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
US6124361A (en) 1997-12-31 2000-09-26 Pfizer Inc Bicyclo[3.1.0]hexanes and related compounds
DE60139107D1 (en) 2000-05-04 2009-08-13 Basf Se Substituierte phenyl-sulfamoyl-carboxamide
ES2169690B1 (es) 2000-10-06 2004-03-16 Diverdrugs Sl Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen.
ES2169691B1 (es) * 2000-10-11 2004-03-16 Diverdrugs Sl Trimeros de n-alquilglicina capaces de bloquear la respuesta a sustancias quimicas, estimulos termicos o mediadores de la inflamacion de receptores neuronales, y composiciones que los contienen.
DK1583541T3 (da) 2002-11-20 2011-04-11 Neuronova Ab Forbindelser og fremgangsmåder til at øge neurogenese
DE10303229B4 (de) 2003-01-28 2007-07-26 Keyneurotek Ag Ambroxol und Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen
US20110052603A1 (en) 2006-10-06 2011-03-03 The Walter And Eliza Hall Institute Of Medical Research method of treatment and agents useful for same
EP1994944A1 (en) * 2007-05-21 2008-11-26 Laboratorios SALVAT, S.A. Polymer conjugate compounds for the inhibition of apoptosis
ES2543222T3 (es) 2008-09-24 2015-08-17 Ribomic Inc. Aptámero para NGF y uso del mismo
RU2410392C2 (ru) * 2009-02-16 2011-01-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН Дипептидные миметики нейротрофинов ngf и bdnf
EP2289882A1 (en) 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer 3-oxopiperazinium derivatives as agonists of nerve growth factor and their use as medicaments
EP2289886A1 (en) * 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoid agonists of nerve growth factor and their use as medicaments
WO2012028959A1 (en) 2010-08-31 2012-03-08 Pablo Villoslada Agonists of neurotrophin receptors and their use as medicaments

Also Published As

Publication number Publication date
CA2809774A1 (en) 2012-03-08
CA2809774C (en) 2019-03-05
MX340233B (es) 2016-07-01
US9453047B2 (en) 2016-09-27
BR112013004662B1 (pt) 2021-09-28
MX2013002329A (es) 2013-07-29
ES2575684T3 (es) 2016-06-30
EP2611775A1 (en) 2013-07-10
EP2611775B8 (en) 2016-06-08
US8791076B2 (en) 2014-07-29
PL2611775T3 (pl) 2016-11-30
CN103270022B (zh) 2015-08-19
PT2611775E (pt) 2016-06-07
US20150005239A1 (en) 2015-01-01
BR112013004662B8 (pt) 2021-12-28
HRP20160553T1 (hr) 2016-09-23
KR20130106384A (ko) 2013-09-27
DK2611775T3 (en) 2016-06-27
US20120052094A1 (en) 2012-03-01
CN103270022A (zh) 2013-08-28
HUE029393T2 (en) 2017-03-28
SI2611775T1 (sl) 2017-01-31
US10106577B2 (en) 2018-10-23
BR112013004662A2 (pt) 2016-08-02
US20170121367A1 (en) 2017-05-04
EP2611775B1 (en) 2016-03-16
AU2011298091A1 (en) 2013-04-18
WO2012028959A1 (en) 2012-03-08
JP5946454B2 (ja) 2016-07-06
AU2011298091B2 (en) 2015-08-20
IL224972A (en) 2015-05-31
JP2013536833A (ja) 2013-09-26
RU2606622C2 (ru) 2017-01-10
RU2013113634A (ru) 2014-10-10

Similar Documents

Publication Publication Date Title
KR101964954B1 (ko) 뉴로트로핀 수용체의 효현제 및 약제로서의 이의 용도
Longo et al. Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease
TWI776886B (zh) Sestrin-gator2交互作用之調節劑及其用途
Zhang et al. RNA interference-mediated knockdown of long-form phosphodiesterase-4D (PDE4D) enzyme reverses amyloid-β42-induced memory deficits in mice
RU2383547C2 (ru) Модуляция бета-катенин/tcf-активируемой транскрипции
HK1258231A1 (zh) 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法
KR20240055788A (ko) 신규한 ras 억제제
US20120237552A1 (en) Peptoid Agonists of Nerve Growth Factor and Their Use as Medicaments
US20160040126A1 (en) Regulation of differentiation into dopaminergic neurons by metalloprotease
US11136348B2 (en) Furostan-3-ol derivatives as skeletal muscle hypertrophic agents
KR20220142363A (ko) 선택적 mTORC2 저해제 및 이의 용도
JP2011510976A (ja) イノシトール１，４，５−三リン酸受容体サブタイプ３の阻害用の組成物
CN114181201B (zh) 作为针对各种神经退行性疾病的潜在治疗剂的新化合物
Yu et al. Thrombospondin1 Enhanced Neuronal Wnt7a and CNTF Expressions by TNFα Signaling Pathway
WO2006090555A1 (ja) Akt活性化剤
JP2012041311A (ja) 絨毛癌の治療剤
JPWO2001073024A1 (ja) 神経栄養因子の発現誘導剤
JP2008044884A (ja) 神経細胞の軸索伸長方法及びストレス耐性付与方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130401

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160830

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20160920

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PN2301 Change of applicant

Patent event date: 20161027

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170419

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171017

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180528

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20181227

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190327

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190328

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220310

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230327

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240319

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20250318

Start annual number: 7

End annual number: 7